ResearcherKing's College HospitalActive in the last 2 years
Evangelia Florou
Matched on ORCID iD 0009-0007-9600-7053; OpenAlex author ID A5076923060. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 3
2026: 4 papers
Papers 4
- Complete pathological response in metastatic pancreatic adenocarcinoma following neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2025.11.018↗
- Can negative lymph node involvement and resection-free margins (ypT1-3N0R0) compete the disease-free survival benefit of a pathologic complete response (ypT0N0… Co-author DOI 10.1016/j.pan.2025.11.020↗
- Vanishing liver metastases in pancreatic cancer: A case report. Co-author DOI 10.3892/ol.2026.15691↗
- Apparent Long-Term Cure Following Conversion Therapy for Initially Unresectable Pancreatic Ductal Adenocarcinoma: A Case Report. Co-author DOI 10.7759/cureus.105912↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Andreas A. Prachalias · 4 shared papers, 2026 · strength 1.68
- Paper Can negative lymph node involvement and resection-free margins (ypT1-3N0R0) compete the disease-free survival benefit o… DOI 10.1016/j.pan.2025.11.020↗
- Paper Vanishing liver metastases in pancreatic cancer: A case report. DOI 10.3892/ol.2026.15691↗
- Paper Apparent Long-Term Cure Following Conversion Therapy for Initially Unresectable Pancreatic Ductal Adenocarcinoma: A Cas… DOI 10.7759/cureus.105912↗
- Yoh Zen · 3 shared papers, 2026 · strength 1.25
- Paper Can negative lymph node involvement and resection-free margins (ypT1-3N0R0) compete the disease-free survival benefit o… DOI 10.1016/j.pan.2025.11.020↗
- Paper Apparent Long-Term Cure Following Conversion Therapy for Initially Unresectable Pancreatic Ductal Adenocarcinoma: A Cas… DOI 10.7759/cureus.105912↗
- Paper Complete pathological response in metastatic pancreatic adenocarcinoma following neoadjuvant therapy. DOI 10.1016/j.pan.2025.11.018↗
- Paul J. Ross · 1 shared paper, 2026 · strength 0.43
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.